Merck Reports Positive Trial Results in Hypercholesterolemia

 The Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe

Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to help address critical unmet needs for patients with hypercholesterolemia and help combat the ongoing cardiovascular (CV) epidemic

https://www.merck.com/news/mercks-enlicitide-decanoate-an-investigational-oral-pcsk9-inhibitor-demonstrated-significantly-greater-ldl-c-reductions-at-eight-weeks-compared-to-guideline-recommended-oral-non-statin-ther/